Lantern Pharma to Host Q3 2025 Financial Results Webcast Highlighting AI-Driven Oncology Progress

Lantern Pharma (NASDAQ: LTRN), an artificial intelligence-driven biotechnology company focused on oncology therapeutics, will conduct a webcast presentation on Thursday, November 13, 2025, to discuss third-quarter operating and financial performance. President and CEO Panna Sharma will lead the management team in reviewing quarterly achievements, clinical trial advancements, and upcoming milestones for the company's artificial intelligence and machine learning initiatives. The webcast represents a significant opportunity for stakeholders to understand how Lantern Pharma's proprietary RADR platform is transforming cancer drug discovery and development.

The company's RADR artificial intelligence and machine learning platform represents a technological breakthrough in oncology research, leveraging over 200 billion oncology-focused data points and utilizing more than 200 advanced machine learning algorithms. This comprehensive approach helps address substantial challenges in oncology drug development that have traditionally required extensive time and financial resources. The platform's capabilities are central to Lantern Pharma's strategy of accelerating the development timeline for cancer therapies while simultaneously reducing associated costs, potentially making innovative treatments more accessible to patients worldwide.

Lantern Pharma's growing pipeline includes multiple therapeutic candidates spanning various cancer indications, including both solid tumors and blood cancers, along with an antibody-drug conjugate program. The company's lead development programs feature a Phase 2 clinical program and multiple Phase 1 clinical trials, demonstrating the practical application of their AI-driven approach. The combined annual market potential for these innovative product candidates is estimated to exceed $15 billion, representing significant commercial opportunity while addressing critical unmet medical needs in oncology. Additional information about the company's developments is available through their newsroom.

The broader context of this announcement reflects the increasing importance of artificial intelligence in pharmaceutical development, particularly in the challenging field of oncology. Companies like Lantern Pharma are at the forefront of integrating advanced computational methods with traditional drug discovery processes, potentially revolutionizing how cancer treatments are identified and developed. The upcoming webcast will provide insights into how these technological advancements are translating into tangible clinical progress and financial performance, offering valuable perspective on the evolving landscape of AI-driven healthcare innovation.